Journal article

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

Michael B Jameson, Danny Rischin, Mark Pegram, John Gutheil, Adam V Patterson, William A Denny, William R Wilson

Cancer Chemotherapy and Pharmacology | SPRINGER | Published : 2010